{{Drugbox
| IUPAC_name               = 3-butyl-7-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone
| image                    = Umespirone.png
| CAS_number               = 107736-98-1
| ATC_prefix               = none
| ATC_suffix               = 
| PubChem                  = 65902
| ChemSpiderID             = 59311
| C = 28 | H = 40 | N = 4 | O = 5
| molecular_weight         = 512.64 g/mol
| smiles                   = O=C1N(C(=O)C2C(=O)N(C(=O)C1C2(C)C)CCCCN4CCN(c3ccccc3OC)CC4)CCCC
| bioavailability          = 
| metabolism               = 
| elimination_half-life    = <small>Unknown but effects last much longer than other azapirones, up to 23 hours after a single dose in human clinical studies.</small><ref name="pmid7957544">{{cite journal | author = Holland RL, Wesnes K, Dietrich B | title = Single dose human pharmacology of umespirone | journal = European Journal of Clinical Pharmacology | volume = 46 | issue = 5 | pages = 461<U+2013>8 | year = 1994 | pmid = 7957544 | doi = | url = }}</ref>
| excretion                = 
| pregnancy_category       = 
| legal_status             = Uncontrolled
| routes_of_administration = Oral
}}

'''Umespirone''' ('''KC-9172''') is a [[drug]] of the [[azapirone]] class which possesses [[anxiolytic]] and [[antipsychotic]] properties.<ref name="pmid1685786">{{cite journal | author = Barnes NM, Costall B, Domeney AM, ''et al.'' | title = The effects of umespirone as a potential anxiolytic and antipsychotic agent | journal = Pharmacology, Biochemistry, and Behavior | volume = 40 | issue = 1 | pages = 89<U+2013>96 | year = 1991 | month = September | pmid = 1685786 | doi = | url = http://linkinghub.elsevier.com/retrieve/pii/0091-3057(91)90326-W}}</ref><ref name="pmid2907649">{{cite journal | author = Ruhland M, Kr<U+00E4>hling H, Fuchs A, Sch<U+00F6>n U | title = KC 9172 (free base of KC 7218)--an antipsychotic/anxiolytic compound. I. Antipsychotic and anxiolytic activity in comparison with chlorpromazine, clozapine, diazepam and buspirone | journal = Pharmacopsychiatry | volume = 21 | issue = 6 | pages = 396<U+2013>8 | year = 1988 | month = November | pmid = 2907649 | doi = | url = }}</ref><ref name="pmid2907650">{{cite journal | author = Kr<U+00E4>hling H, Fuchs A, Ruhland M, Sch<U+00F6>n U, Mol F, Tulp M | title = KC 9172 (free base of KC 7218)--an antipsychotic/anxiolytic compound. II. Discrimination from typical neuroleptics and benzodiazepine-like minor tranquilizers | journal = Pharmacopsychiatry | volume = 21 | issue = 6 | pages = 399<U+2013>401 | year = 1988 | month = November | pmid = 2907650 | doi = | url = }}</ref><ref name="pmid1671523">{{cite journal | author = Schmidt WJ, Kr<U+00E4>hling H, Ruhland M | title = Antagonism of AP-5-induced sniffing stereotypy links umespirone to atypical antipsychotics | journal = Life Sciences | volume = 48 | issue = 6 | pages = 499<U+2013>505 | year = 1991 | pmid = 1671523 | doi = | url = }}</ref> It behaves as a [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[partial agonist]] (K<sub>i</sub> = 15 nM), [[D2 receptor|D<sub>2</sub> receptor]] partial agonist (K<sub>i</sub> = 23 nM), and [[alpha-1 adrenergic receptor|<U+03B1><sub>1</sub>-adrenoceptor]] [[receptor antagonist]] (K<sub>i</sub> = 14 nM), and also has weak affinity for the [[sigma receptor]] (K<sub>i</sub> = 558 nM).<ref name="pmid1685786">{{cite journal | author = Barnes NM, Costall B, Domeney AM, ''et al.'' | title = The effects of umespirone as a potential anxiolytic and antipsychotic agent | journal = Pharmacology, Biochemistry, and Behavior | volume = 40 | issue = 1 | pages = 89<U+2013>96 | year = 1991 | month = September | pmid = 1685786 | doi = | url = http://linkinghub.elsevier.com/retrieve/pii/0091-3057(91)90326-W}}</ref><ref name="pmid1361441">{{cite journal | author = Ahlenius S, Wijkstr<U+00F6>m A | title = Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat | journal = European Journal of Pharmacology | volume = 222 | issue = 1 | pages = 69<U+2013>74 | year = 1992 | month = November | pmid = 1361441 | doi = | url = }}</ref><ref name="pmid1970425">{{cite journal | author = Itzhak Y, Ruhland M, Kr<U+00E4>hling H | title = Binding of umespirone to the sigma receptor: evidence for multiple affinity states | journal = Neuropharmacology | volume = 29 | issue = 2 | pages = 181<U+2013>4 | year = 1990 | month = February | pmid = 1970425 | doi = | url = }}</ref> Unlike other anxiolytics and antipsychotics, umespirone produces minimal [[sedation]], [[cognitive deficit|cognitive/memory impairment]], [[catalepsy]], and [[extrapyramidal symptom]]s.<ref name="pmid1671523">{{cite journal | author = Schmidt WJ, Kr<U+00E4>hling H, Ruhland M | title = Antagonism of AP-5-induced sniffing stereotypy links umespirone to atypical antipsychotics | journal = Life Sciences | volume = 48 | issue = 6 | pages = 499<U+2013>505 | year = 1991 | pmid = 1671523 | doi = | url = }}</ref><ref name="pmid1361441">{{cite journal | author = Ahlenius S, Wijkstr<U+00F6>m A | title = Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat | journal = European Journal of Pharmacology | volume = 222 | issue = 1 | pages = 69<U+2013>74 | year = 1992 | month = November | pmid = 1361441 | doi = | url = }}</ref><ref name="pmid7957544">{{cite journal | author = Holland RL, Wesnes K, Dietrich B | title = Single dose human pharmacology of umespirone | journal = European Journal of Clinical Pharmacology | volume = 46 | issue = 5 | pages = 461<U+2013>8 | year = 1994 | pmid = 7957544 | doi = | url = }}</ref>

== See also ==
* [[Azapirone]]

== References ==
{{Reflist|2}}


{{Antipsychotics}}
{{Anxiolytics}}
{{Antidepressants}}
{{Adrenergics}}
{{Dopaminergics}}
{{Sigmaergics}}
{{Serotonergics}}


{{pharmacology-stub}}
